How to optimize activated partial thromboplastin time (APTT) testing: solutions to establishing and verifying normal reference intervals and assessing APTT reagents for sensitivity to heparin, lupus anticoagulant, and clotting factors
Abstract
The activated partial thromboplastin time (APTT) assay is a very common coagulation test, used for several reasons. The test is conventionally used for assessing the contact factor (intrinsic) pathway of blood coagulation, and thus for screening deficiencies in this pathway, most typically factors VIII, IX, and XI. The APTT is also sensitive to contact factor deficiencies, including factor XII, prekallikrein, and high-molecular-weight kininogen. The APTT may also be elevated in a variety of conditions, including liver disease, vitamin K deficiency, and disseminated intravascular coagulation. The APTT can also be used for monitoring unfractionated heparin (UFH) therapy, as well as for screening lupus anticoagulant (LA) or for assessing thrombosis risk. Which of these separate uses is important to a given laboratory or clinician depends on the laboratory and the clinical context. For example, UFH sensitivity is important in hospital-based laboratories, where UFH therapy is used, but not in hospital-based laboratories where low-molecular-weight heparin (LMWH) is largely employed or where UFH may be assessed by anti-factor Xa testing, or in private/community laboratories not associated with a hospital system. High sensitivity to (low levels of) factors VIII, IX, and XI is generally preferred, as their deficiencies are clinically significant. Also preferred, but not usually achieved, is low sensitivity to factor XII and other contact factors, as these deficiencies are usually asymptomatic. Nevertheless, a good knowledge of factor sensitivity is usually needed, if only to help explain the reasons for a prolonged APTT in a given patient, or whether factor testing or other investigation is required. A good working knowledge of reagents sensitivity to LA is also advisable, especially when the reagent is used as part of a LA test panel, or else as a "general-purpose screening reagent." The current report is aimed at providing some guidance around these questions, and is intended as a kind of "how to" guide, that will enable laboratories to assess APTT reagents in regard to their sensitivity to heparin, LA, and clotting factors. The report also provides some advice on generation of normal reference ranges, as well as solutions for troubleshooting prolonged APTTs, when performing factor testing or searching for inhibitors.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Some APTT reagents are much more sensitive than others.
“some aPTT reagents are much more sensitive than others.46”
Cites
Update of the guidelines for lupus anticoagulant detection
PENGO, V., TRIPODI, A., REBER, G., RAND, J. H., ORTEL, T. L., GALLI, M., & DE GROOT, P. G. (2009) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03555.x · Cited by 1,197 · see citing works
Hirsh, J., Bauer, K. A., Donati, M. B., et al. (2008) · CHEST Journal · doi:10.1378/chest.08-0689 · Cited by 755 · see citing works
Guidelines on the investigation and management of antiphospholipid syndrome
Keeling, D., Mackie, I., Moore, G. W., Greer, I. A., Greaves, M., & British Committee for Standards in Haematology (2012) · British Journal of Haematology · doi:10.1111/j.1365-2141.2012.09037.x · Cited by 740 · see citing works
Gosselin, R. C., Adcock, D. M., Bates, S. M., Douxfils, J., Favaloro, E. J., Gouin‐Thibault, I., Guillermo, C., Kawai, Y., Lindhoff‐Last, E., & Kitchen, S. (2018) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1627480 · Cited by 395 · see citing works
Self-citationKamal, A. H., Tefferi, A., & Pruthi, R. K. (2007) · Mayo Clinic Proceedings · doi:10.4065/82.7.864 · Cited by 365 · see citing works
Olson, J. D., Arkin, C. F., Brandt, J. T., et al. (1998) · PubMed · Cited by 240 · see citing works
Vandiver, J. W., & Vondracek, T. G. (2012) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.2011.01049.x · Cited by 237 · see citing works
Quality Standards for Sample Collection in Coagulation Testing
Lippi, G., Salvagno, G. L., Montagnana, M., Lima-Oliveira, G., Guidi, G. C., & Favaloro, E. J. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1315961 · Cited by 196 · see citing works
Self-citationQuality Standards for Sample Processing, Transportation, and Storage in Hemostasis Testing
Funk, D. M. A., Lippi, G., & Favaloro, E. J. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1319768 · Cited by 148 · see citing works
Self-citationClinical Use of the Activated Partial Thromboplastin Time and Prothrombin Time for Screening
Levy, J. H., Szlam, F., Wolberg, A. S., et al. (2014) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2014.06.005 · Cited by 140 · see citing works
Lippi, G., von Meyer, A., Cadamuro, J., & Simundic, A.-M. (2019) · Diagnosis · doi:10.1515/dx-2018-0018 · Cited by 135 · see citing works
Self-citationInterference in Coagulation Testing: Focus on Spurious Hemolysis, Icterus, and Lipemia
Plebani, M., Favaloro, E. J., & Lippi, G. (2012) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0032-1328972 · Cited by 131 · see citing works
Self-citationLippi, G., & Favaloro, E. J. (2014) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2014-0767 · Cited by 113 · see citing works
Self-citationThe evolution of anticoagulant therapy.
Franchini, M., Liumbruno, G. M., Bonfanti, C., & Lippi, G. (2016) · PubMed Central · doi:10.2450/2015.0096-15 · Cited by 98 · see citing works
Self-citationLaboratory testing of anticoagulants: the present and the future
Favaloro, E. J., Lippi, G., & Koutts, J. (2011) · Pathology · doi:10.1097/pat.0b013e32834bf5f4 · Cited by 95 · see citing works
Self-citationDirect oral anticoagulants: analysis of worldwide use and popularity using Google trends
Lippi, G., Mattiuzzi, C., Cervellin, G., & Favaloro, E. J. (2017) · Annals of Translational Medicine · doi:10.21037/atm.2017.06.65 · Cited by 91 · see citing works
Self-citationClement, B., Gausman, J. N., & Marlar, R. A. (2016) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0036-1581128 · Cited by 86 · see citing works
Activated Partial Thromboplastin Time: New Tricks for an Old Dogma
Lippi, G., & Favaloro, E. J. (2008) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0028-1104539 · Cited by 82 · see citing works
Self-citationFavaloro, E. J., & Wong, R. C. W. (2014) · Pathology · doi:10.1097/pat.0000000000000142 · Cited by 75 · see citing works
Self-citationTherapeutic monitoring of unfractionated heparin – trials and tribulations
Baluwala, I., Favaloro, E. J., & Pasalic, L. (2017) · Expert Review of Hematology · doi:10.1080/17474086.2017.1345306 · Cited by 73 · see citing works
Self-citationFavaloro, E. J., Pasalic, L., Curnow, J. L., & Lippi, G. (2017) · Current Drug Metabolism · doi:10.2174/1389200218666170417124035 · Cited by 52 · see citing works
Self-citationDetermination of APTT factor sensitivity – the misguiding guideline
Lawrie, A. S., Kitchen, S., Efthymiou, M., Mackie, I. J., & Machin, S. J. (2013) · International Journal of Laboratory Hematology · doi:10.1111/ijlh.12109 · Cited by 50 · see citing works
Clinical and laboratory diagnosis of heparin induced thrombocytopenia: an update
Favaloro, E. J., McCaughan, G. J. B., & Pasalic, L. (2017) · Pathology · doi:10.1016/j.pathol.2017.02.005 · Cited by 50 · see citing works
Self-citationFavaloro, E. J., Pasalic, L., & Lippi, G. (2017) · Pathology · doi:10.1016/j.pathol.2017.04.011 · Cited by 36 · see citing works
Self-citationFavaloro, E. J. (2018) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0038-1667342 · Cited by 35 · see citing works
Self-citationIntersubject variability in the anticoagulant response to heparin in vitro
Bjornsson, T. D., & Wolfram, K. M. (1982) · European Journal of Clinical Pharmacology · doi:10.1007/bf00542044 · Cited by 29 · see citing works
Manzato, F., Mengoni, A., Grilenzoni, A., et al. (1998) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.1998.168 · Cited by 27 · see citing works
Laboratory tests for identification or exclusion of heparin induced thrombocytopenia: HIT or miss?
Favaloro, E. J. (2017) · American Journal of Hematology · doi:10.1002/ajh.24979 · Cited by 27 · see citing works
Self-citationMalbora, B., & Bilaloğlu, E. (2015) · Pediatric Hematology and Oncology · doi:10.3109/08880018.2015.1065302 · Cited by 24 · see citing works
Prolonged Activated Partial Thromboplastin Time
Ames, P. R. J., Graf, M. E., Archer, J., Scarpato, N., & Iannaccone, L. (2014) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/1076029614541516 · Cited by 24 · see citing works
Favaloro, E. J. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_4 · Cited by 23 · see citing works
Self-citationKershaw, G. W. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_5 · Cited by 22 · see citing works
Self-citationPerformance and interpretation of mixing tests in coagulation
Kershaw, G. (2017) · Methods in molecular biology · doi:10.1007/978-1-4939-7196-1_6 · Cited by 16 · see citing works
Self-citationTesting for dabigatran and rivaroxaban by clinical laboratories
Cott, E. M. V., Smock, K. J., Chen, D., et al. (2016) · American Journal of Hematology · doi:10.1002/ajh.24494 · Cited by 8 · see citing works
Novel (Oral) Anticoagulant Challenges in Surgery
Blennerhassett, R. C., Favaloro, E. J., & Pasalic, L. (2017) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0037-1602667 · Cited by 7 · see citing works
Self-citationPoli, G., Castiglioni, P., Montagnana, M., et al. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.11.17 · Cited by 6 · see citing works
Lippi, G., Mengoni, A., & Manzato, F. (1999) · Cited by 3 · see citing works
Self-citationMorris, W. H., & Kumar, A. (2007) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.74.electronic_suppl_1.s13 · Cited by 2 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Devreese, K. M. J., de Groot, P. G., de Laat, B., Erkan, D., Favaloro, E. J., Mackie, I., Martinuzzo, M., Ortel, T. L., Pengo, V., Rand, J. H., et al. (2020) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.15047 · Cited by 439 · see citing works
Self-citationFavaloro, E. J. (2020) · American Journal of Hematology · doi:10.1002/ajh.25669 · Cited by 53 · see citing works
Self-citationMixing studies for lupus anticoagulant: mostly yes, sometimes no
Favaloro, E. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2019-1240 · Cited by 20 · see citing works
Self-citation
- Authors
- Kershaw, G., Mohammed, S., Lippi, G., & Favaloro, E.
- Affiliations
- Westmead Hospital (AU)
- University of Verona (IT)
- Corresponding author
- Favaloro, Emmanuel
- Venue
- Seminars in Thrombosis and Hemostasis
- Publisher
- Georg Thieme Verlag KG
- Published
- 2019-01-10
- Volume
- 45
- Issue
- 01
- Pages
- 022-035
- ISSN
- 0094-6176 (ISSN-L)
- 1098-9064
- OpenAlex
- W2910835955
- Cited by
- 96
- References
- 38
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 15 · 2023: 16 · 2022: 20 · 2021: 15 · 2020: 14 · 2019: 5
- FWCI
- 9.29
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Seminars in Thrombosis and Hemostasis (publishedVersion)
- PubMed (publishedVersion)
- Funders
- NSW Health Pathology
- Topics
- Health Sciences › Medicine › Physiology › Clinical Laboratory Practices and Quality Control
- Health Sciences › Medicine › Hematology › Blood Coagulation and Thrombosis Mechanisms
- Health Sciences › Medicine › Genetics › Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Keywords
- activated partial thromboplastin time, lupus anticoagulant, heparin sensitivity, intrinsic coagulation pathway, factor XII deficiency, anticoagulants, heparin therapy monitoring, low molecular weight heparin
- MeSH terms
- Blood Coagulation Factors, Heparin, Humans, Partial Thromboplastin Time, Reference Values, Lupus Coagulation Inhibitor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
